Curative Biotechnology Inc
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying… Read more
Curative Biotechnology Inc (CUBT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: 0.037x
Based on the latest financial reports, Curative Biotechnology Inc (CUBT) has a cash flow conversion efficiency ratio of 0.037x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-185.27K) by net assets ($-4.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Curative Biotechnology Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Curative Biotechnology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Curative Biotechnology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Curative Biotechnology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Indomobil Multi Jasa Tbk
JK:IMJS
|
0.089x |
|
Electro-Sensors Inc
NASDAQ:ELSE
|
0.027x |
|
Implanet SA
PA:ALIMP
|
0.224x |
|
Nuheara Ltd
AU:NUH
|
-1.082x |
|
Pool Advista Indonesia Tbk
JK:POOL
|
0.022x |
|
UMediC Group Berhad
KLSE:0256
|
-0.034x |
|
ADVFN Plc
PINK:AVFCF
|
-0.118x |
|
NeuroMetrix Inc
NASDAQ:NURO
|
-0.132x |
Annual Cash Flow Conversion Efficiency for Curative Biotechnology Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Curative Biotechnology Inc from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-4.91 Million | $-1.02 Million | 0.208x | +34.46% |
| 2023-12-31 | $-3.14 Million | $-486.58K | 0.155x | +107.00% |
| 2022-12-31 | $-20.53 Million | $-1.54 Million | 0.075x | -23.70% |
| 2021-12-31 | $-16.36 Million | $-1.60 Million | 0.098x | +133.19% |
| 2020-12-31 | $-4.52 Million | $-190.09K | 0.042x | +9914.88% |
| 2019-12-31 | $-357.33K | $-150.00 | 0.000x | +92.90% |
| 2018-12-31 | $-689.28K | $-150.00 | 0.000x | -4.34% |
| 2017-12-31 | $-659.37K | $-150.00 | 0.000x | -97.54% |
| 2016-12-31 | $-636.38K | $-5.89K | 0.009x | +393.09% |
| 2015-12-31 | $-618.98K | $1.96K | -0.003x | -111.64% |
| 2014-12-31 | $-773.80K | $-20.99K | 0.027x | -46.45% |
| 2013-12-31 | $-704.28K | $-35.68K | 0.051x | -- |